Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Presence of active clinical synovitis in at least 2 joints, 1 of which must have been a small joint, for a minimum of 8 weeks prior to screening~* Onset of persistent symptoms ≤ 2 years prior to screening~* Positive test result for anticyclic citrullinated peptides 2~* Methotrexate naive or with minimum exposure to methotrexate, defined as no more than 10 mg/week for ≤4 weeks and no methotrexate dose for 1 month prior to screening visit~* Biologic naive, including no treatment with an investigational biologic prior to screening~* Disease Activity Score 28 based on C-reactive protein score ≥3.2 at screening~* Withdrawal from any treatment with chloroquine, hydroxychloroquine, and/or sulfasalazine (wash-out) for a minimum of 28 days prior to randomization~* If receiving oral corticosteroids, on a stable low dose (≤ 10 mg/day prednisone equivalent) for at least 4 weeks~* Able to undergo magnetic resonance imaging~Key Exclusion Criteria:~* Meeting diagnostic criteria for other rheumatic disease (eg, lupus erythematosus)~* Treatment with an intravenous, intramuscular, or intraarticular corticosteroid within 4 weeks prior to randomization~* Scheduled for or anticipating joint replacement surgery~* Presence of concomitant illness likely to require systemic glucocorticosteroid therapy during the study, in the opinion of the investigator~* History of malignancy in the last 5 years~* Any serious bacterial infection within the last 3 months not treated or resolved with antibiotics, or any chronic or recurrent bacterial infection~* At risk for tuberculosis~* Evidence of active or latent bacterial or viral infection at the time of potential enrollment, including human immunodeficiency or herpes zoster virus or cytomegalovirus that resolved less than 2 months prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept, 125 mg, plus methotrexate, 2.5 mg (Type: ACTIVE_COMPARATOR): Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period
- Methotrexate, 2.5 mg, plus abatacept placebo (Type: ACTIVE_COMPARATOR): Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period
- Abatacept, 125 mg, plus methotrexate placebo (Type: ACTIVE_COMPARATOR): Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period

Based on this trial design, predict the completion outcome and termination type (if applicable).